

DATE:	18 December 2025
TO:	All Hematologists
FROM:	Molecular Pathology Program, Alberta Precision Laboratories
RE:	BCR::ABL Connect Care Ordering Changes

PLEASE POST OR DISTRIBUTE AS WIDELY AS APPROPRIATE

Key Message

- A pop-up question will be added to BCR::ABL Connect Care to better screen BCR::ABL monitor testing for CML and reduce inappropriate testing.

Background

- BCR::ABL qRT-PCR monitoring is standard of care for the assessment of treatment responsiveness in Chronic Myelogenous Leukemia (CML)
- Different established monitoring intervals exist for multiple patient scenarios (on time on therapy, trial off drug, treatment failure, etc)
- To better screen BCR::ABL orders for appropriateness, a question pop-up will be added to Connect Care that will contain info fields that will help determine the appropriate testing interval and decrease inappropriate orders.
- All requests that do not meet testing intervals will be reviewed by pathology for appropriateness prior to cancellation
- This process will ONLY apply to BCR::ABL testing in CML patients (does not apply to B-ALL testing)

How this will impact you

- Hematology will need to complete the questions as best as possible to help establish appropriate monitoring intervals.
- A “additional clinical history” is included in the pop-up window to allow for any exclusions or extenuating factors that alter testing intervals not addressed in the question pop-up (e.g. B-ALL, potential therapy failure/resistance)
- Given the wide range of testing intervals and variable access patients have to APL sample collection sites in the community, a window of time will be used during review of the appropriate testing interval (up to 2 weeks) when reviewing the request

Action Required

- **Hematologist:** Review the appropriate testing intervals as listed in the most recent Hematology GURU guidelines for CML and complete the pop-up questions in Connect Care when ordering.

Effective December 18, 2025



Questions/Concerns

- Dr. Adrian Box, Provincial Medical/Scientific Director, Molecular Pathology
Adrian.box@albertaprecisionlabs.ca
- Dr. Cheryl Mather, Medical Lead, Molecular Pathology North
Cheryl.mather@albertaprecisionlabs.ca

Approved by

- Dr. Adrian Box, Medical/Scientific Director, Molecular Pathology Program
- Dr. Cheryl Mather, Medical Lead, Molecular Pathology North
- Christine Frantz, Operations Director, Genetics & Genomics / Molecular Pathology
- Dr. Carolyn O'Hara, Chief Medical Laboratory Officer (Interim), Alberta Precision Laboratories